Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin

---

Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

Murray Epstein, MD;Nancy L. Reaven, MA;Susan E. Funk, MBA;Karen J. McGaughey, PhD;Nina Oestreicher, PhD;John Knispel, MD

September 16th 2015

ArticleARTICLES

---

Participating Faculty: Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

September 16th 2015

ArticleAUTHOR INDEX

---

eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS

September 16th 2015

ArticleARTICLES

---

eAPPENDIX 3. ADVERSE OUTCOME DEFINITIONS

September 16th 2015

ArticleARTICLES

---

eAPPENDIX 1. ICD-9 CODES USED FOR CLASSIFICATION OF COMORBIDITIES

September 16th 2015

ArticleARTICLES